
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Human Cancer Biology |
Authors' Affiliations: 1 Department of Surgery and 2 Regenerative Medicine Institute and Department of Medicine, National University of Ireland, Galway, Ireland
Requests for reprints: Michael Kerin, Department of Surgery, Clinical Science Institute, National University of Ireland Galway, Ireland. E-mail: michael.kerin{at}nuigalway.ie or Roisin Dwyer, Department of Surgery, Clinical Science Institute, National University of Ireland Galway, Ireland. Phone: 91-544637; Fax: 11-353-091-494509; E-mail: roisin.dwyer{at}nuigalway.ie.
Purpose: Major barriers to effective adenovirus-based gene therapy include induction of an immune response and tumor-specific targeting of vectors. The use of mesenchymal stem cells (MSC) as systemic delivery vehicles for therapeutic genes has been proposed as a result of their combined ability to home in on the tumor site and evade the host immune response. This study is aimed at investigating factors mediating homing of human MSCs to breast cancer primary cultures and cell lines in vitro and in vivo.
Experimental Design: Fluorescently labeled MSCs were given to mice bearing breast cancer xenografts, and tumor tissue was harvested to detect MSC engraftment. MSC migration in response to primary breast tumors in vitro was quantified, and chemokines secreted by tumor cells were identified. The role of monocyte chemotactic protein-1 (MCP-1) in cell migration was investigated using antibodies and standards of the chemokine. Serum MCP-1 was measured in 125 breast cancer patients and 86 healthy controls.
Results: Engrafted MSCs were detected in metastatic breast tumors in mice after systemic administration. There was a significant increase in MSC migration in response to primary breast tumor cells in vitro (6-fold to 11-fold increase). Tumor explants secreted a variety of chemokines including GRO
, MCP-1, and stromal cell–derived factor-1
. An MCP-1 antibody caused a significant decrease (37-42%) in MSC migration to tumors. Serum MCP-1 levels were significantly higher in postmenopausal breast cancer patients than age-matched controls (P < 0.05).
Conclusions: These results highlight a role for tumor-secreted MCP-1 in stimulating MSC migration and support the potential of these cells as tumor-targeted delivery vehicles for therapeutic agents.
This article has been cited by other articles:
![]() |
F. Zhang, S. Tsai, K. Kato, D. Yamanouchi, C. Wang, S. Rafii, B. Liu, and K. C. Kent Transforming Growth Factor-{beta} Promotes Recruitment of Bone Marrow Cells and Bone Marrow-derived Mesenchymal Stem Cells through Stimulation of MCP-1 Production in Vascular Smooth Muscle Cells J. Biol. Chem., June 26, 2009; 284(26): 17564 - 17574. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Gao, W. Priebe, J. Glod, and D. Banerjee Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell-Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell-Conditioned Medium Stem Cells, April 1, 2009; 27(4): 857 - 865. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Coffelt, F. C. Marini, K. Watson, K. J. Zwezdaryk, J. L. Dembinski, H. L. LaMarca, S. L. Tomchuck, K. H. zu Bentrup, E. S. Danka, S. L. Henkle, et al. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells PNAS, March 10, 2009; 106(10): 3806 - 3811. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lord-Dufour, I. B. Copland, L.-C. Levros Jr., M. Post, A. Das, C. Khosla, J. Galipeau, E. Rassart, and B. Annabi Evidence for Transcriptional Regulation of the Glucose-6-Phosphate Transporter by HIF-1{alpha}: Targeting G6PT with Mumbaistatin Analogs in Hypoxic Mesenchymal Stromal Cells Stem Cells, March 1, 2009; 27(3): 489 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kyriakou, N. Rabin, A. Pizzey, A. Nathwani, and K. Yong Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model Haematologica, October 1, 2008; 93(10): 1457 - 1465. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lazennec and C. Jorgensen Concise Review: Adult Multipotent Stromal Cells and Cancer: Risk or Benefit? Stem Cells, June 1, 2008; 26(6): 1387 - 1394. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Lowery, N. Miller, R. E. McNeill, and M. J. Kerin MicroRNAs as Prognostic Indicators and Therapeutic Targets: Potential Effect on Breast Cancer Management Clin. Cancer Res., January 15, 2008; 14(2): 360 - 365. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |